Hasta la próxima

Auto reproducción

Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas

14 vistas • 07/18/23
Compartir
Empotrar
administrator
administrator
Suscriptores
0

Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.

Mostrar más
0 Comentarios sort Ordenar por
Comentarios de Facebook

Hasta la próxima

Auto reproducción